MMS Holdings Expert Insights Blog
Experts at MMS share their insights on trending
topics in the pharmaceutical industry.
FREE DOWNLOAD: Lay Summary Whitepaper
This complimentary lay summary whitepaper will explain: the ins and outs of lay summary writing, the importance of starting a pilot program, a checklist for lay reviewers, and strategic advice for becoming more transparent. Click on the image for the full...
MMS Holdings Leverages Medrio to Accelerate Clinical Trial Process for Study Sponsors Through New Contract
The agreement demonstrates the value of Medrio’s support resources in facilitating mutual success for CROs and study sponsors. SAN FRANCISCO (May 08, 2019) – MMS Holdings – an award-winning, data-focused contract research organization (CRO) – has successfully...
Being Inclusive, the Open Door Policy, and True Success: A Conversation with Diederik Van Niekerk
In this Expert Insights interview, we sit down with our South African leadership, Diederik Van Niekerk, Operations Manager at MMS in Bloemfontein, South Africa, to discuss his detailed approach for effective team-building, his views on work/life balance, and growth....
Part 4: The Case for Better Health History Records – Overcoming Barriers to Medical Records Access
In Part 3 of this medical histories series, the focus centered on defining many of the barriers that clinical investigators face when attempting to procure adequate medical records for subject eligibility determination. While the list of potential issues appeared...
PhUSE: Retrospective vs. Proactive Anonymization of Narratives
Exerpt from whitepaper originally published by PhUSE on March 14, 2019 by project co-leads – Rashmi Dodia, MS, RAC and Gregory Campbell, BS Executive Summary Ever since policy 0070 was first introduced in 2016, there have been continuing concerns and challenges among...
GHP Recognises MMS Holdings in the 2019 Biotechnology Awards Winners
Staffordshire, United Kingdom (March 13, 2019) – GHP Magazine has awarded MMS Holdings Most Outstanding Global CRO in the 2019 Biotechnology Awards. Covering a variety of verticals, including bio agriculture, bio services, bio industrial and biopharmaceutical, the...
Part 3: The Case for Better Health History Records – Identifying Barriers to Access
In Part 2 of this series, the focus was on ensuring adequate information to support subject eligibility. Knowing how many and what kinds of records to review is key to developing a robust review program to ensure subject eligibility, as is knowing how to reconcile...
How #OneMMS Actively Supports Rare Disease Day
Rare diseases are often overlooked, but they affect many individuals. There may be as many as 7,000 rare diseases affecting approximately 25-30 million people in the US alone, according to the National Institutes of Health (NIH). Rare diseases are defined as...
Part 2: The Case for Better Health History Records – How Much History is Needed and How Should it be Reviewed?
Part 1 of this medical histories series focused on the regulations relevant to clinical trial subject eligibility, and the possible issues which can arise when ineligible subjects are enrolled. As noted, the outcomes vary depending on whether you are a clinical site,...